Department of Surgery and Center of Esophageal Diseases, Teine Keijinkai Hospital, 1-40 Maeda, Teine-Ku, Sapporo, Hokkaido, 006-8555, Japan.
Department of Surgery, Teine Keijinkai Hospital, 1-40 Maeda1-12, Teine-Ku, Sapporo, Hokkaido, 006-8555, Japan.
Trials. 2023 Jun 19;24(1):412. doi: 10.1186/s13063-023-07435-5.
After esophagectomy for esophageal and esophagogastric cancer, more than half of patients have lost > 10% of their body weight at 12 months. In most cases, the gastric remnant is used for reconstruction after esophagectomy. One of the most serious nutritional complications of this technique is delayed gastric emptying caused by gastric remnant mobilization and denervation of the vagus nerve. The aim of the PYloroplasty versus No Intervention in GAstric REmnant REconstruction after Oesophagectomy (PYNI-GAREREO) trial is to analyze the clinical outcome of modified Horsley pyloroplasty (mH-P) as a method of preventing delayed gastric emptying.
The PYNI-GAREREO trial is designed as an open randomized, single-center superiority trial. Patients will be randomly allocated to undergo gastric remnant reconstruction with mH-P (intervention group) or no intervention (control group) in parallel groups. All patients with esophageal cancer or esophagogastric cancer planning to undergo curative minimally invasive esophagectomy will be considered for inclusion. A total of 140 patients will be included in the study and randomized between the groups in a 1:1 ratio. The primary outcome is the body weight change at 6 months postoperatively, and the secondary outcomes are the nutritional status, postoperative complications, functional outcome, and quality of life until 1 year postoperatively.
We hypothesize that mH-P after minimally invasive esophagectomy more effectively maintains patients' nutritional status than no pyloroplasty.
UMIN Clinical Trials Registry UMIN000045104. Registered on 25 August 2021. https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051346 .
食管癌和食管胃交界癌患者行食管切除术后,超过一半的患者在 12 个月时体重大于 10%。在大多数情况下,胃残端用于食管切除术后的重建。该技术最严重的营养并发症之一是胃残端移动和迷走神经去神经导致的胃排空延迟。胃残端重建后改良 Horsley 幽门成形术(mH-P)预防胃排空延迟的临床疗效分析(PYNI-GAREREO)试验旨在分析改良 Horsley 幽门成形术(mH-P)作为预防胃排空延迟的方法的临床效果。
PYNI-GAREREO 试验设计为开放随机、单中心优效性试验。患者将被随机分为接受 mH-P(干预组)或不干预(对照组)的胃残端重建平行组。所有计划行微创根治性食管癌切除术的食管癌或食管胃交界癌患者均被考虑纳入。研究共纳入 140 例患者,按 1:1 比例随机分组。主要结局为术后 6 个月的体重变化,次要结局为营养状况、术后并发症、功能结局和术后 1 年的生活质量。
我们假设微创食管切除术后行 mH-P 比不做幽门成形术更有效地维持患者的营养状态。
UMIN 临床研究注册 UMIN000045104。注册于 2021 年 8 月 25 日。https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051346。